CPC A61K 36/185 (2013.01) [A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/352 (2013.01); A61K 31/355 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/5545 (2017.08); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] | 8 Claims |
1. A method of treatment of endometrial cancer comprising administering to a patient an effective amount of a chemotherapeutic agent selected from the group consisting of: paclitaxel, carboplatin, doxorubicin, cisplatin, docetaxel, gemcitabine, capecitabine, and combinations thereof; and coadministering an effective amount of a composition comprising a cannabis extract (CE), said CE comprising cannabidiol (CBD) at a concentration of between 60% and 99% by weight of the CE and having a pH of between 3.5 and 6, wherein the composition is for intravaginal delivery.
|